文献速递系统性红斑狼疮类风湿关节炎其他结缔组织病

自身免疫病中炎症小体激活的临床病理意义研究进展

Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.
PubMed 文献 · Arthritis Rheumatol · 2020-01-15

本文综述炎症小体在自身免疫病中的激活机制与临床病理意义。炎症小体激活caspase-1,促使IL-1β和IL-18成熟释放,介导局部与全身炎症。人类研究显示系统性红斑狼疮、类风湿关节炎、晶体性关节病和干燥综合征患者中存在这些细胞因子水平升高及炎症小体相关分子激活改变,动物模型 genetic 或药物靶向炎症小体可改善炎症与组织损伤。

要点

  • 炎症小体激活促进IL-1β和IL-18成熟,介导自身免疫病炎症反应。
  • SLE、RA、晶体性关节病和干燥综合征中可见炎症小体相关分子改变。
  • 动物模型靶向炎症小体可改善炎症和组织损伤,支持其致病作用。

核心结论

  • 炎症小体激活在风湿性疾病中具有临床病理意义,遗传或药物靶向炎症小体在动物模型中可改善炎症与组织损伤,支持其致病作用。

研究设计与样本

  • 综述,基于近期研究汇总炎症小体激活在风湿性疾病及相关疾病中的临床病理意义与治疗靶向。

主要发现

  • 人类研究显示SLE、RA、晶体性关节病和干燥综合征中IL-1β和IL-18水平升高、炎症小体相关分子激活改变和/或存在炎症小体激活物。
  • 上述改变见于肾脏、关节、唾液腺等原发靶器官以及心血管系统。
  • 动物模型中遗传或药物靶向炎症小体可改善炎症和组织损伤。
  • 炎症小体由模式识别受体、procaspase-1及连接二者的衔接分子组成,激活后caspase-1将proIL-1β和proIL-18转化为成熟IL-1β和IL-18。

临床怎么用

  • 炎症小体激活及其下游IL-1β、IL-18可作为风湿性疾病临床病理评估的参考线索。
  • 靶向炎症小体是风湿性疾病及相关疾病潜在的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune diseases are characterized by dysregulated immune tolerance to self and inflammatory damage to tissues and organs. The development of inflammation involves multiple innate and adaptive immune pathways. Inflammasomes are multimeric cytosolic protein complexes that form to mediate host immune responses upon recognizing pathogen- or damage-associated molecular patterns via pattern-recognition receptors (PRRs). The accelerating pace of inflammasome research has demonstrated important roles for inflammasome activation in many pathologic conditions, including infectious, metabolic, autoinflammatory, and autoimmune diseases. The inflammasome generally comprises a PRR, procaspase 1, and an adaptor molecule connecting the PRR and procaspase 1. Upon inflammasome activation, procaspase 1 becomes active caspase 1 that converts pro-interleukin-1β (proIL-1β) and proIL-18 into mature and active IL-1β and IL-18, respectively. The cytokines IL-1β and IL-18 have multipotent effects on immune and nonimmune cells and induce and promote systemic and local inflammatory responses. Human studies have shown increased levels of these cytokines, altered activation of inflammasome-related molecules, and/or the presence of inflammasome activators in rheumatic diseases, including systemic lupus erythematosus, rheumatoid arthritis, crystal-induced arthropathies, and Sjögren's syndrome. Such changes are found in the primary target organs, such as the kidneys, joints, and salivary glands, as well as in the cardiovascular system. In animal models of rheumatic diseases, inflammation and tissue damage improve upon genetic or pharmacologic targeting of the inflammasome, supporting its pathogenic role. Herein, we review the clinicopathologic significance and therapeutic targeting of inflammasome activation in rheumatic diseases and related conditions based on recent findings.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kahlenberg JM, Kang I. Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases. Arthritis Rheumatol. 2020. PMID: 31562704. doi:10.1002/art.41127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。